Clinical trials: Metabolic Associated Fatty Liver Disease, open to volunteers
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
To determine the effect of MTHF supplementation on serum folate and homocysteine level, metabolic, nutritional status, liver function, and PPARα and TNFα gene expression in patients with MASLD
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- MASLD (NCT07740109)
- Testing
- 5-methyltetrahydrofolate (5-MTHF)
- Where
- Iran
- Volunteers
- 44 people
- Sponsor
- Tabriz University of Medical Sciences
Metabolic Dysfunction-associated Steatotic Liver Disease
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1…
- Trial name
- NCT06703450
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
Hepatic Steatosis, Fatty Liver
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Living donor liver transplantation (LDLT) is a critical therapeutic modality for patients with end-stage liver disease and hepatic malignancies.
- Conditions
- Hepatic Steatosis, Fatty Liver, Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- GODEX (NCT07922720)
- Testing
- GODEX® capsule treatment group
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Fatty Liver Disease
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).
- Trial name
- NCT06585982
- Testing
- Treatment, Control
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Diponegoro
Non-Alcoholic Fatty Liver Disease
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT06717828
- Testing
- Tai Chi Exercise, Regular Exercise, Control
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Provincial Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Type 2 Diabetes, Fatty Liver
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty…
- Trial name
- NCT06989723
- Testing
- Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Bundang Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease
Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation.
- Trial name
- NCT07373769
- Testing
- Ultrasound and magentic resonance imaging
- Where
- Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Food Insecurity
Implementing Food Referrals for Equity and Sustained Health
Food insecurity (FI) disproportionately affects those who have been historically marginalized and significantly contributes to poor health outcomes.
- Trial name
- I-FRESH (NCT06661538)
- Testing
- Food Security Screening & Referral Program
- Where
- 2 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Non-Alcoholic Fatty Liver Disease
BeijngFH Health Cohort Study
Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease.
- Trial name
- FHCS (NCT05546086)
- Where
- China
- Volunteers
- 8,103 people
- Sponsor
- Beijing Friendship Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI > 25)
- Trial name
- NCT07193927
- Testing
- Lactiplantibacillus plantarum Probiotic Mixture
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- AB Biotics, SA
Non-alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic…
- Trial name
- NCT07358546
- Testing
- Efimosfermin alfa
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis)
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
- Trial name
- NCT07581951
- Testing
- HSK31679
- Where
- China
- Volunteers
- 886 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
NAFLD, Obesity, Morbid
Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease
The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors…
- Conditions
- NAFLD, Obesity, Morbid, Comorbidities and Coexisting Conditions
- Trial name
- NCT05554224
- Testing
- To propose diagnostic tests for liver diseases before surgical decisions.
- Where
- Spain
- Volunteers
- 1,104 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
MAFLD
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
A 12-month prospective observational cohort study assessing eGDR's utility in diagnosing MAFLD (via FibroScan® CAP ≥248 dB/m) and correlating it with steatosis/fibrosis severity.
- Trial name
- NCT06923215
- Volunteers
- 30 people
- Sponsor
- Assiut University
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Quantitative Ultrasound to Assess Steatotic Liver Disease in Children
This research study is being conducted to find out more about advanced ultrasound techniques to non-invasively evaluate liver disease in children.
- Trial name
- NCT06706856
- Testing
- MR exam, US exam, Blood draw
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego